Stuart A. Arbuckle - 15 Nov 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
15 Nov 2021
Net transactions value
-$562
Form type
4
Filing time
16 Nov 2021, 15:05:49 UTC
Previous filing
17 Jun 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $374 -2 -0% $186.99 41,104 15 Nov 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale $188 -1 -0% $187.80 41,103 15 Nov 2021 Direct F1
holding VRTX Common Stock 140 15 Nov 2021 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $186.99 (range $186.67 to $187.31).
F3 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.